LOUISVILLE, Colo., Dec. 5 /PRNewswire-FirstCall/ -- Replidyne, Inc. announced today that President and Chief Executive Officer Kenneth J. Collins will participate on the New and Powerful Anti-infectives panel at the RBC Capital Markets 2007 Healthcare Conference. The panel discussion will take place at 11:00 am ET on Thursday, December 13, 2007 at the Westin Times Square in New York City.
A live audio webcast of the panel discussion will be available on the investor relations section of the company’s website at http://www.Replidyne.com. The webcast will be archived and available on Replidyne’s website after the event for a period of 30 days.
About Replidyne, Inc.
Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne’s lead product, faropenem medoxomil, is a novel oral community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne’s second drug candidate, REP8839, is a topical anti-infective product candidate in development for the treatment of skin and wound infections, including methicillin-resistant S. aureus (MRSA) infections. Replidyne’s investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and C. difficile-associated disease (CDAD). Replidyne is pursuing the development of other novel anti-infective programs based on its in-house discovery research.
CONTACT: Sabrina B. Oei, Dir. Investor & Public Relations of Replidyne,
Inc., +1-303-996-5535
Web site: http://www.replidyne.com/
